Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence [0.03%]
Ivosidenib治疗急性髓系白血病患者有效性和安全性的更新：现有证据综述
Galia Stemer,Jacob M Rowe,Yishai Ofran
Galia Stemer
The isocitrate dehydrogenase enzyme, catalyzing isocitrate conversion to α-ketoglutarate (αKG) in both the cell cytoplasm and mitochondria, contributes to the production of dihydronicotinamide-adenine dinucleotide phosphate (NADPH) as a r...
Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review [0.03%]
培甘司匹在儿童、青少年和年轻成人急性淋巴细胞白血病患者中的临床应用：综述
Cynthia Bender,Luke Maese,Maria Carter-Febres et al.
Cynthia Bender et al.
Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy representing 25% of all cancers in children less than 15 years of age. Significant improvements in survival and cure rates have been made over the past four decad...
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma [0.03%]
BCL2家族抑制剂在多发性骨髓瘤的生物学和治疗中的作用
Vikas A Gupta,James Ackley,Jonathan L Kaufman et al.
Vikas A Gupta et al.
Although much progress has been made in the treatment of multiple myeloma, the majority of patients fail to be cured and require numerous lines of therapy. Inhibitors of the BCL2 family represent an exciting new class of drugs with a novel ...
The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study [0.03%]
肥胖对成人急性淋巴细胞白血病患者预后影响的单中心回顾性研究
Qiuju Liu,Brittny Major,Jennifer Le-Rademacher et al.
Qiuju Liu et al.
Introduction: Obesity is a worldwide problem that is related to cardiac disease, thrombosis and cancer. However, little is known about the impact of obesity on the outcomes of adult acute lymphoblastic leukemia (ALL) pati...
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy [0.03%]
评估Blinatumomab治疗复发/难治性急性淋巴细胞白血病的效果：设计、开发和治疗方法的选择地位
Audrey M Sigmund,Kieran D Sahasrabudhe,Bhavana Bhatnagar
Audrey M Sigmund
Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortu...
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy [0.03%]
年龄对接受伊布替尼作为初始治疗的CLL患者生存率的影响
Chaitra Ujjani,Anthony Mato,Brian T Hill et al.
Chaitra Ujjani et al.
Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reporte...
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma [0.03%]
Venetoclax在慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中的作用扩大
Michael Schieber,Shuo Ma
Michael Schieber
The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression represents a common survival adaption in cancer. Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relaps...
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma [0.03%]
布伦妥欣在经典型霍奇金淋巴瘤中的应用及其地位变迁
Catherine Lai,Adrese Michael Kandahari,Chaitra Ujjani
Catherine Lai
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreate...
Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1 [0.03%]
CRISPR/Cas9敲除BIRC5基因诱导HL-60和KG-1白血病细胞株凋亡及抑制增殖
Manizheh Narimani,Mohammadreza Sharifi,Ali Jalili
Manizheh Narimani
Introduction: Human Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) which encodes survivin exhibits multiple biological activities, such as cell proliferation and apoptosis. Survivin is overexpressed in num...
Giovanna Carrà,Antonio Cartellà,Beatrice Maffeo et al.
Giovanna Carrà et al.
Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development ...